Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PTGX vs CRNX, SYRE, TGTX: FCF Margin % Comparison
For the Biotechnology subindustry, Protagonist Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagonist Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics (MEX:PTGX) has a FCF Margin % of 102.53% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Protagonist Therapeutics and its competitors. According to the industry distribution chart, Protagonist Therapeutics ranks #34 out of 956 companies in the Biotechnology industry, placing it in the top 3.6%.
Is Protagonist Therapeutics' FCF Margin % too high?
Protagonist Therapeutics' current FCF Margin % is 102.53%. Based on the distribution chart, Protagonist Therapeutics ranks #34 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' FCF Margin % compare to CRNX and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #34 out of 956 companies for FCF Margin %. This places Protagonist Therapeutics in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current FCF Margin % is 102.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current FCF Margin % of 102.53%. The stock's GF Value™ is MXN943.19, compared to a current price of MXN1,565.33 — trading 66% above its estimated fair value. The current FCF Margin % is 102.53%. Protagonist Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current FCF Margin % is 102.53% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of MXN1,565.33 is trading 66% above its estimated GF Value™ of MXN943.19.
Key valuation signals for MEX:PTGX:
FCF Margin %: 102.53%
GF Value™: MXN943.19 vs. price of MXN1,565.33 (66% above fair value)
No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
53GF Score
Get the complete analysis for MEX:PTGX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PTGX has been successfully added to your 
